US FDA uncovers faults at Aurobindo Pharma’s Anakapalli facility; shares fall
Live MintAurobindo Pharma share price fell over a percent on Friday after reports that US Food and Drug Administration officials found multiple faults at a plant run by the drugmaker. The auditors have uncovered “deficient” manufacturing equipment cleaning and storage controls during a visit last month to the company's facility in Anakapalli, eastern India, according to a FDA report obtained by Bloomberg News through a Freedom of Information Act request. Aurobindo Pharma had last month said the FDA recorded “procedural” observations following the inspection of its factory in Anakapalli in May. In a separate filing on June 29, Aurobindo Pharma said Auro PR Inc, its step-down wholly owned subsidiary based at Caguas, Puerto Rico, was undertaking a restructuring of its facility to enhance production volume, after completion of commitment for product supply to third party by early July 2023.
History of this topic
Large cap stock hits 52-week high after US FDA conducts inspection at subsidiary
Live Mint
Aurobindo Pharma share price rises more than 1% on regulatory clearance of plant
Live Mint
Aurobindo shares double on US show
Live Mint
Aurobindo Pharma shares surge on Q2 earnings
Live Mint
Tough times again for Aurobindo Pharma as USFDA reverses stance
Live Mint
USFDA raps Aurobindo Pharma
The HinduDiscover Related
)
)
)
)
)
)
)
